- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04820010
Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
Purpose: To evaluate the clinical outcome of patients with refractory Neurotrophic Keratopathy (NK) in stages 2 and 3 treated with topical insulin.
Methods: A retrospective, observational analysis of eyes with NK in stages 2 and 3 refractory to standard medical and/or surgical treatment which were treated with topical insulin. Topical insulin (1 unit per mL) was applied 4 times a day; treatment was continued until persistent epithelial defect (PED) or ulcer resolved and then tapered accordingly. The primary outcome of the study was the complete resolution of the PED or ulcer. Best-corrected visual acuity (BCVA), days until complete resolution as well as anterior segment photographs were obtained.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study type
Retrospective, observational, single-center study at the Department of Ophthalmology of Centro Hospitalar Vila Nova de Gaia e Espinho, EPE.
Data was obtained from patients' medical records and anterior segment photographs from October 1, 2018 to November 1, 2020.
Each participant and/or relative was given a detailed explanation and a written informed consent regarding possible alternatives, risks and benefits of off-label use of topical insulin drops. This study was approved by the board of Centro Hospitalar de Vila Nova de Gaia e Espinho (UIEC-2020-981914339595fa024c567ec5). This study complied with the tenets of the Declaration of Helsinki.
Patient selection
Patients included in this study were provided from the Cornea department of the Ophthalmology center in Centro Hospitalar de Vila Nova de Gaia e Espinho. Every patient included had an established diagnosis of NK (ICD10: H16.2) in stages 2 or 3 that was refractory to standard medical and/or surgical treatment and underwent treatment with topical insulin. All patients underwent complete ophthalmological exam including best-corrected visual acuity, slit-lamp examination, corneal sensitivity in the center and four quadrants of the cornea and fundoscopic evaluation. NK was graded based on slit-lamp and fluorescein stain findings - stage 2: epithelial defect (with or without a rim of loose epithelium) without stromal ulceration; stage 3: corneal ulceration and/or stromal lysis.
Topical insulin preparation and administration
Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2ºC) and were applied four times a day. A therapeutic corneal CL was placed in every patient and fluoroquinolone drops were applied to prevent possible CL side-effects.
Treatment was continued until NK PED or Ulcer resolved and tapered accordingly. Patients would discontinue topical insulin if the condition did not improve within 30 days or worsen. Follow-up was ensured on the 3rd,5th, and 7th day and then individualized during the full-extent of treatment. Anterior segment photos were taken on each visit.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Vila Nova de Gaia, Portugal
- Centro Hospitalar Vila Nova de Gaia e Espinho
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria included:
• Eyes with established diagnosis of NK in stages 2 or 3 refractory to standard treatment* that underwent topical insulin treatment.
The diagnosis of NK was based on the following criteria:
- Decreased or absence of corneal sensation; AND
- Corneal injury [PED and/or corneal ulcer] refractory to standard treatment*; AND
Clinical history of conditions related to trigeminal innervation impairment;
- Standard treatment - lubrication with artificial tears, topical and/or oral antibiotics, topical and/or oral steroids, antiviral drugs, punctal plugs, therapeutic CL, amniotic membrane surgery and temporary tarsorrhaphy.´
We excluded every patient with corneal ulcer and signs of infection.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days until closure of the corneal wound
Time Frame: Time until complete resolution of corneal wound, assessed up to 8 weeks
|
Days
|
Time until complete resolution of corneal wound, assessed up to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best-corrected Visual Acuity improvement
Time Frame: Before and after treatment completion, assessed up to 8 weeks
|
logMAR
|
Before and after treatment completion, assessed up to 8 weeks
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12776388755f18199947f
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurotrophic Keratitis
-
Dompé Farmaceutici S.p.ARecruitingNeurotrophic KeratitisUnited States
-
University of California, Los AngelesRecruiting
-
University of AlbertaWithdrawn
-
Sight Medical Doctors PLLCDompé, US, Inc.RecruitingNeurotrophic Keratitis | Neurotrophic Ulcer | Neurotrophic Corneal Ulcer | Neurotrophic KeratoconjunctivitisUnited States
-
Recordati Rare DiseasesSyneos HealthRecruitingNeurotrophic KeratitisUnited Kingdom, Spain, Italy, United States, Germany, France, Hungary
-
Dompé Farmaceutici S.p.ACompletedNeurotrophic KeratitisUnited States
-
Stanford UniversityCompleted
-
BRIM Biotechnology Inc.Not yet recruiting
-
Claris Biotherapeutics, Inc.RecruitingNeurotrophic KeratitisUnited States, Canada
-
Dompé Farmaceutici S.p.ADompé USCompletedNeurotrophic KeratitisUnited States
Clinical Trials on Topical Insulin
-
Alexandria UniversityRecruiting
-
Universiti Kebangsaan Malaysia Medical CentreRecruiting
-
Cairo UniversityNot yet recruiting
-
Zagazig UniversityNot yet recruitingAcne Scars - Mixed Atrophic and Hypertrophic
-
Centre hospitalier de l'Université de Montréal...Recruiting
-
University of Ljubljana, Faculty of MedicineMedical University of Graz Department of Pediatrics and Adolescent Medicine... and other collaboratorsCompleted
-
National Taiwan University HospitalCompletedCorneal Epithelial Defects After Ocular SurgeriesTaiwan
-
Universidad de AntioquiaINNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES... and other collaboratorsWithdrawnLeishmaniasis, CutaneousColombia
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Stanford UniversityUniversity of Pennsylvania; University of California, Davis; Oregon Health and... and other collaboratorsRecruiting